The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Guardant Health (GH) one of those stocks right now? By taking ...

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health ...

Canaccord analyst Kyle Mikson raised the firm’s price target on Guardant Health (GH) to $60 from $42 and keeps a Buy rating on the shares. The ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price boosted by research analysts at The Goldman Sachs Group ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Explore Guardant Health's Q4 2024 earnings report, highlighting record revenue, Shield's commercial milestones, and a strong 2025 growth outlook.

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.